DFAN14A

                                 SCHEDULE 14A

                           SCHEDULE 14A INFORMATION

                   PROXY STATEMENT PURSUANT TO SECTION 14(A)
                    OF THE SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant [ ]

Filed by a Party other than the Registrant [X]

Check the appropriate box:

[ ] Preliminary Proxy Statement
[ ] Confidential, For Use of the Commission Only (as permitted by
    Rule 14a-6(e)(2))
[ ] Definitive Proxy Statement
[ ] Definitive Additional Materials
[X] Soliciting Material Pursuant to Section 240.14a-12


                      SYNAPTIC PHARMACEUTICAL CORPORATION

                            -----------------------

               (Name of Registrant as Specified in its Charter)

                            -----------------------

                                H. LUNDBECK A/S

   (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.

[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     (1)  Title of each class of securities to which transaction applies:
     (2)  Aggregate number of securities to which transaction applies:
     (3)  Per unit price or other underlying value of transaction computed
          pursuant to Exchange Act Rule 0-11 (set forth the amount on which
          the filing fee is calculated and state how it was determined):
     (4)  Proposed maximum aggregate value of transactions:
     (5)  Total fee paid:
- ----------
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act
    Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
    paid previously. Identify the previous filing by registration statement
    number, or the Form or Schedule and the date of its filing.

     (1)  Amount Previously Paid:
     (2)  Form, Schedule or Registration Statement No.:
     (3)  Filing Party:
     (4)  Date Filed:





                                                                             2

Set forth as Exhibit 99.1 is a transcript of the Synaptic acquisition
teleconference held by H. Lundbeck A/S on November 21, 2002.

**THIS FILING IS IDENTICAL TO THE FILING MADE ON NOVEMBER 21, 2O02 (ACCESSION
NUMBER 0000950157-02-000796). THIS FILING IS BEING MADE TODAY FOR THE SOLE
PURPOSE OF CORRECTLY INDEXING THE FILING TO H. LUNDBECK A/S'S APPROPRIATE
EDGAR CENTRAL INDEX KEY (CIK) CODE.**


Please note that the merger described in the teleconference is contingent on
approval by the Synaptic stockholders, regulatory approvals and other
customary closing conditions, including obtaining Hart-Scott-Rodino approval.

Synaptic is a pioneer in the development of pharmaceuticals that target G
protein-coupled receptors (GPCRs) to achieve superior efficacy and safety in
the treatment of disorders such as depression, diabetes, obesity, pain and
incontinence. As of November 21, 2002, Synaptic is collaborating with
Grunenthal GmbH on discovering compounds for the alleviation of pain and with
Kissei Pharmaceutical Co., Ltd. to identify novel G protein- coupled receptors
that can provide new drug discovery targets for Kissei. Glaxo Group Limited,
Eli Lilly and Company, Novartis Pharma A.G. and Ranbaxy Laboratories Limited
have also been granted licenses by Synaptic.

H. Lundbeck A/S is an international pharmaceutical company engaged in the
research and development, production, marketing and sale of drugs for the
treatment of psychiatric and neurological disorders. In 2001, the Company's
revenue was DKK 7.7 billion. The number of employees is approx. 4,800.

ADVISORS
Lundbeck was advised by JPMorgan. Synaptic was advised by Bank of
America Securities.

FORWARD LOOKING STATEMENTS
The forward-looking statements contained in this announcement are based on the
management's current expectations concerning certain future events and
results. These are, of course, subject to uncertainty, and actual results may
therefore differ materially from those expressed by the statements. Further,
some of the expectations are based upon assumptions about future events, which
may turn out to be incorrect.

ADDITIONAL INFORMATION
Stockholders of Synaptic are urged to read the proxy statement that Synaptic
will file on Schedule 14A with the Securities and Exchange Commission ("SEC")
when it becomes available, and any other relevant documents filed or to be
filed in the future with the SEC because those documents contain important
information about Synaptic, the proposed transactions and related matters.
Investors and security holders can obtain free copies of the proxy statement
at Synaptic's web site, www.synapticcorp.com or by contacting Investor
Relations, Synaptic Pharmaceutical Corporation, 215 College Road, Paramus, NJ
07652 (Telephone: (201) 261-1331, ext. 1410). Investors and security holders
can also obtain free copies of the proxy statement and other documents filed
by Synaptic and henceforth by Lundbeck with the SEC in connection with the
proposed transactions at the SEC's web site at www.sec.gov.

In addition to the proxy statement, Synaptic files annual, quarterly and
special reports, proxy statements and other information with the SEC, each of
which are available at the SEC's web site at www.sec.gov. Lundbeck has not
previously filed any reports or other information with the SEC because
Lundbeck has no securities registered pursuant to the Securities Exchange Act
of 1934, as amended. You may also read and copy any reports, statements and
other information filed by Synaptic and henceforth by Lundbeck at the





                                                                             3

SEC public reference room at 450 Fifth Street, N.W., Washington, D.C. 20549.
Please call the SEC at 1-800-SEC-0330 for further information.

Synaptic, Lundbeck, and their respective directors, executive officers and
certain members of management and other employees may be deemed to be
participants in the solicitation of proxies of Synaptic's stockholders to
approve the proposed transactions. Such individuals may have interests in the
transactions, including as a result of holding options or shares of Synaptic's
stock. Information regarding Lundbeck and its directors and officers is
contained in its DFAN 14A, filed with the SEC on November 21, 2002.
Information regarding Synaptic and its directors and officers is contained in
its proxy statement on Schedule 14A, filed with the SEC on April 8, 2002.

INFORMATION REGARDING PARTICIPANTS ON BEHALF OF LUNDBECK
Set forth below is the name, business address, principal occupation or
employment and citizenship of each director and executive officer of Lundbeck.
The name of each person who is a director of Lundbeck is marked with an
asterisk. The business address of each person listed below is 9 Ottiliavej,
DK-2500 Valby, Copenhagen, Denmark. As of the date of this filing, none of the
directors or executive officers listed below individually held any options or
shares of Synaptic securities.




Name and Business Address                    Principal Occupation or Employment                  Citizenship
                                                                                           
- -------------------------------------------- --------------------------------------------------  -----------------------
ERIK SPRUNK-JANSEN                           President and Chief Executive Officer of Lundbeck   Denmark
- -------------------------------------------- --------------------------------------------------  -----------------------
CLAUS BRAESTRUP                              Executive Vice President, Research and              Denmark
                                             Development of Lundbeck
- -------------------------------------------- --------------------------------------------------  -----------------------
LARS BANG                                    Senior Vice President, Commercial Operations,       Denmark
                                             Europe and Overseas of Lundbeck
- -------------------------------------------- --------------------------------------------------  -----------------------
HARALD CONRADI-LARSEN                        Senior Vice President, Human Resource               Norway
                                             Management of Lundbeck
- -------------------------------------------- --------------------------------------------------  -----------------------
                                             Senior Vice President, Corporate Affairs and
STIG LOKKE PEDERSEN                          Commercial Operations, America and Asia of          Denmark
                                             Lundbeck
- -------------------------------------------- --------------------------------------------------  -----------------------
HANS HENRIK MUNCH-JENSEN                     Senior Vice President, Corporate Finance and        Denmark
                                             Communication of Lundbeck
- -------------------------------------------- --------------------------------------------------  -----------------------
OLE MOESTRUP                                 Senior Vice President, Strategic Marketing of       Denmark
                                             Lundbeck
- -------------------------------------------- --------------------------------------------------  -----------------------
MORTEN KOLD MIKKELSEN                        Senior Vice President, Supply Operations and        Denmark
                                             Engineering of Lundbeck
- -------------------------------------------- --------------------------------------------------  -----------------------
ARNE V. JENSEN*                              Chairman                                            Denmark
- -------------------------------------------- --------------------------------------------------  -----------------------
OLE STEEN ANDERSEN                           Executive Vice President, Chief Financial Officer ofDenmark
                                             Danfoss
- -------------------------------------------- --------------------------------------------------  -----------------------
LARS BRUHN*                                  President and Chief Executive Officer of Bruhn      Denmark
                                             Group
- -------------------------------------------- --------------------------------------------------  -----------------------
PETER KURSTEIN*                              Executive Vice President of Radiometer Medical      Denmark
- -------------------------------------------- --------------------------------------------------  -----------------------
SVEN DYRLOV MADSEN*                          Director                                            Denmark
- -------------------------------------------- --------------------------------------------------  -----------------------







                                                                             4



                                                                                           
- -------------------------------------------- --------------------------------------------------  -----------------------
OLE VAHLGREN*                                Vice President, U.S. Operations of Lundbeck, Inc.   Denmark
- -------------------------------------------- --------------------------------------------------  -----------------------
FLEMMING LINDELOV*                           Chief Executive Officer of Royal Scandinavia        Denmark
- -------------------------------------------- --------------------------------------------------  -----------------------
JAN GOTTLIEBSEN*                             Teamleader Liquid & Sterile Production of Lundbeck  Denmark
- -------------------------------------------- --------------------------------------------------  -----------------------
BIRGIT BUNDGAARD ROSENMEIER*                 Head of Department, Quality Sterile Production of   Denmark
                                             Lundbeck
- -------------------------------------------- --------------------------------------------------  -----------------------
TORBEN SKARSFELDT*                           Head of Department, Corporate Licensing of          Denmark
                                             Lundbeck
- -------------------------------------------- --------------------------------------------------  -----------------------







                                                                            4


                              INDEX TO EXHIBITS


Exhibit No.         Exhibit
- -----------         -------

    99.1            Transcript of the Synaptic Acquisition Teleconference held
                    by H. Lundbeck A/S on November 21, 2002

EX-99.1

                                                                  Exhibit 99.1


Welcome to this teleconference, following our release earlier today where we
announced that we had signed a definitive merger agreement with Synaptic
Pharmaceutical Corporation, a U.S. based company in the U.S.

Please turn to Slide 2.

TEXT OF SLIDE 2

     This presentation contains forward-looking statements that reflect the
     Management's current views with respect to certain future events and
     financial performance.

     Statements containing the outlook for 2002 and the following years
     naturally involve uncertainties, and consequently actual results may
     differ materially from those projected or implied in the forward-looking
     statements.

     Further, certain forward-looking statements are based on assumptions of
     future events, which may prove not to be accurate.

With me today is our Executive Vice President, head of R & D, Dr. Claus
Braestrup, and I would now hand over to him. Please, Claus.

Claus Braestrup:

Hello, this is Claus Braestrup. I'd like to briefly mention some of the
reasons behind the process, and also the rationale and the expectations.
Basically, we come from the situation where we see our self continue to grow,
and we expect that we will significantly increase our research and development
investment also in the coming several years, and based on that, we need the
staff, the people, and the possibility to continue to build a strong pipeline.
In Copenhagen, we have very good access to good science and good people, but
it's becoming increasingly difficult to actually find sufficient number of
people with the right experience and the right knowledge. After we consider
that United States is today and will probably maintain that position for
several years to come, as being the primary inventive organization or
structure for new drugs. It seems that both the innovation in new drugs, and
also the market for drugs is coming out of the United States, and based on
that, we have decided that the best





                                                                             2

approach for us would be to establish ourselves on a research and later
development unit in the United States. We have looked at various possibilities
for establishing ourselves, and we have come to the decision that an
acquisition would be the best approach, because it provides an immediate
remedy to our issue, and it wouldn't take us several years before we would
actually have an up and running organization, and therefore we have decided to
look for an acquisition.

The question next on the next slide is why have we selected Synaptic? We have
known Synaptic for many years, and we think that Synaptic is a perfect
platform to expand our CNS research in the United States. We know the people
there well, and we are very impressed with what they have achieved over the
years. We also see that they have a very strong intellectual property position
in G Coupled Receptors, and we continue to note that many of the drugs that
are relevant for the CNS are also related to these G Coupled Receptors.

We believe that by joining forces between Lundbeck Copenhagen and Synaptic, we
would significantly strengthen our franchise in the CNS and we would be able
to increase the number of projects that we can work on in various disorders,
at this point in time, in particular, we note that Synaptic had projects both
in depression, anxiety and psychosis, which could be very useful in the
future. We believe then that this would cause a number of new chemical
entities to be brought into development. The group there presently is about 90
people in research, the discovery organization, and they have an excellent
scientific reputation, and they have actually shown that they can handle the
field of G Coupled Receptors, and also other targets which are relevant, and
therefore we believe that this organization would be a very useful platform
for our continued development. Also, we believe that it's important that the
location of Synaptic is such that you can actually reach Synaptic on direct
pipeline from Copenhagen, which would make the interaction between the
research organizations very well-functioning.

The basis for the transaction is shown on the next slide, and I propose Hans
Henrik Munch-Jensen take you through the terms.

Hans Henrik Munch-Jensen:

If you would like to go to slide four please. As we said in our announcement,
we are making a bid of $6.50 for each Synaptic share, will be paid in cash.
Equity value will be 120.5 million US dollar, and the implied tech value is
92.8 million US dollars. We expect the closing of the transaction end of
February, beginning of March 2003, I will a little later come back and talk a
bit more about the transaction period here. This transaction of course
requires the approval of a majority of the Synaptic voting





                                                                             3

stock, and we have signed a shareholder agreement with Warburg Pincus, which
is the owner of approximately 35% of Synaptic's shares, and they have agreed
to vote in favor of the proposed transaction and against any alternate
transaction while the Merger Agreement is in effect. Of course, certain Deal
Protections in. First of all, Synaptic has agreed to vote their shares in
favor of the proposed transaction and against any alternate transaction while
the Merger Agreement is in effect and they will have to pay a break-up fee if
it does a transaction with another partner.

Please turn to slide five, the financial impact for Lundbeck. First of all,
this transaction will have no financial impact for 2002. We still expect an
increase in revenue of 20-25% compared to 2001, while the operating profit is
expected to increase by 25-30% compared to 2001. Based on these expectations
for 2001 [sic], the company also in 2003 expects to reach the company's
long-term financial goals, which are an increase in revenue of 10-12% and an
increase in operating profit of 12-15%. From a P & L perspective, the Synaptic
acquisition will add approximately for a period of ten months next year, DKK
300 million to the R & D expenses including depreciations. Based on this, the
R & D expenses will not exceed the corporate goal of investing approximately
20% of sales in the research & development annually. The transaction will be
paid in cash. Cap Ex spending in 2003 will be at the level in 2001, where, as
you know, we acquired the remaining part of Dukoulten, in Germany, a
transaction of a similar size and structure as this one, and will be at the
level of 2001, which is approximately DKK 2 billion. Our existing cash
position is about DKK 1 billion. This will be paid as I said cash, and our
cash position at the end of 2003, we estimate will be at the same size as it
is currently.

Please turn to slide 6. I guess you are all more or less familiar with the
process that follows such an acquisition here. I would like to say that the
merger is contingent on approval by Synaptic stock holders, regulatory
approvals, and other customary closing conditions. Synaptic intends to hold a
special meeting of its stockholders to approve the merger in the first quarter
of 2003, and to close the transaction shortly thereafter. Warburg Pincus,
private equity, Synaptic's largest stockholder, has signed a voting agreement
with Lundbeck to vote its shares in favor of the transactions. Warburg Pincus
owns approximately 35% of Synaptic. The transaction has been approved by the
Board of Directors of Synaptic and Lundbeck. What will happen now, is that
there will be a drafting of a proxy that will be sent for SEC review, and
after that the proxy will be distributed to the Synaptic shareholders, which
will then





                                                                             4

have a period of time, of course to review this, and then there will be an
annual general meeting, at Synaptic, where the same shareholders will vote on
the proposal, and as I said, Warburg Pincus have agreed that their shares will
be voting in favor of the agreement.

That was that formal presentation, and operator, now we would like to take
questions please.


Operator:

Thank you sir. We will now pause for questions. If you would like to ask a
question, please press the number one on the telephone keypad. To cancel,
simply press the hash, or the pound sign. Once again, to ask a question, it's
number one on the keypad, and the hash or the pound sign to cancel. Our first
question is from Martin Paekroy, from Danske Securities. Please go ahead.

Martin P:

This is Martin P at the Danske Securities. I have two questions. Looking at
the pipeline from Synaptic, you can see they have different products outside
the CNS area, such as incontinence and pain, and also within diabetes. What do
you expect to do with these products, and secondly, now you have created a
platform as you said yourself, with acquiring -- buying a company in the U.S.
Could you comment a bit about your strategy now with respect to a potential
sales force, build-up or acquisition in the U.S.?

Claus Braestrup:

Claus Braestrup here, I'll take the first question. The pipeline of Synaptic
presently includes as you said projects outside the CNS. Our plan will be over
a period of time to focus all the efforts at Synaptic on CNS diseases, which
is already today more than 50% of what they are doing, and then we would look
at the projects which are outside the CNS, and we would of course exploit the
value of which is inherent in the projects, and that is why we will have a
period of time, how many months that would be I won't say, but in that period
of time we would evaluate the projects, and seek to take the value out of
them. And Hans-Henrik on sales force.

Hans Henrik Munch-Jensen:

We have now created as you say Martin, a platform in the U.S. and Claus has
given you the reason why we have done that. This will of course mean that we
are still as we have





                                                                             5

said looking in the U.S. for ways of establishing Lundbeck also in terms of
sales and distribution, and the decision to acquire Synaptic does not change
this, so we are still seeking out possibilities, how to establish Lundbeck,
also in the U.S. in terms of distribution and sales.

Martin:

Thank you.

Operator:

Thank you, our next question is from Annette Slekia, from Nordia Securities.
Please go ahead.

Annette:

This is Annette Slekia from Nordia Securities. My first question will be, how
will you insure that key scientist is staying within the company, and my
second question is that I know that there is a new CEO in the company. What
kind of role is he playing now?

Hans Henrik Munch-Jensen:

I think Claus Braestrup again.

Claus Braestrup:

The issue there is that it is an inherent risk of acquiring research
organizations that the scientists will decide to leave. If that happens, we
will have lost some of the value, not all of it, because there are the
projects, and the intellectual property, but definitely it is important to us
to retain the important scientists. We believe that -- and the reason behind
- -- the reasoning behind that is that we know a number of the scientists
because we have had a lot of interaction with that group over the years, and
we have noticed there that we have a very good common way of doing things, and
a common approach and view on science and what should be done, so based on
that, I think that will have the understanding of the group that working
together with Lundbeck would be worthwhile. That's the first part.

Hans Henrik Munch-Jensen:

The second part, we will, in the way that it's done in the U.S., we will
establish a retention program for the employees which will make it worthwhile
for them to stay at least for one year, and we expect then that after that
year, they will, they will consider their present working





                                                                             6

conditions as very worthwhile. Regarding the present CEO, he actually entered
into that position very recently, I think less than two months ago, with the
intention of establishing a separate company which was fully fledged, and
stand-alone company, and that means that his position has changed dramatically
in this regard, and we will have to discuss with him what that means to him.

Operator:

Thank you.

Karl [inaudible] Henrik here, as well from Nordia
Securities.  Could I ask you, could you [inaudible] a little
bit about this lead compound for depression, called SCT 11,
[inaudible] the fact that [inaudible] and how far that
program is in Phase I trials?

Karl [inaudible]:

The project that is most ahead is a compound for depression. The compound has
been developed by Synaptic, and is now currently in clinical Phase I. The
mechanism of action has not been disclosed, probably be disclosed in the near
future. The mechanism of action is known to us. Apparently the situation there
is that we are awaiting a further evaluation of the technical details of that
compound, the due diligence that we have done ... of the project is.

[inaudible]

Due diligence does not give the possibility to make a proper
evaluation of how far ahead the project is, that means there
are still technical issues for that compound, which we'll
have to look into.

Karl [inaudible]:

O.K. Thank you.

Operator:

Thank you, our next question is from Michael Entsig from Alfred Berg. Please
go ahead.

Michael Entsig:

Hi, this is Michael Entsig from Alfred Berg. I have two questions, I think
both are for you, Claus. Could you briefly in technical terms describe what
differentiates Synaptic's technology from other companies who target GPCRs,





                                                                             7

and the other question is also regarding this pipeline. Could you -- I mean, I
assume you bought this company also in part because of the pipeline. Do you
have any clause which will allow you to escape this deal if you find any
problems with the pipeline, or what?

Claus Braestrup:

I think we -- if you ask for what is it that they can do better than others,
then I think the answer to that is that they have been working on this
specific receptor type for many years, and they have established all the
necessary technologies, lots of advanced technologies, but that advanced
technology is not proprietary to Synaptic, which means that in principle,
other companies and laboratories can work with the same technology, however,
it takes a long time to be really expert in the field, and they [inaudible]
experts [inaudible] competitive advantage that brings you success. On top of
that, they have an IPR position where they have a patent application and
issued patents on a number of these receptors, which means that Synaptic and a
few other companies actually dominate this field which contains a lot of
profit [inaudible]. It's a combination of experience and IPR position.

Michael:

O.K., I had some trouble hearing you, but as far as I can hear, you're also
buying access to targets, was that correct?

Claus Braestrup:

Yes. Is there anything wrong [inaudible] telephone work? We might pass the
target on, and have a strong proprietary position on all the targets, and this
of course is [inaudible] and then they have a number of projects which are
currently in pre-technical eight cases, and of course we will look further for
[inaudible] projects. We have conducted a due diligence through a number
people who are on the projects in detail, but we know the details of the
projects very well, and we acquired to be a certain action, and we feel
confident of that.

Michael:

O.K., thank you.







                                                                             8

Operator:

Thank you. Our next question is from Jung Park from [inaudible] Analystics.
Please go ahead and announce your location.

Jung Park:

Yes, hi. My question is regarding the required regulatory approval for this
deal, whether there are any FDA approvals. I didn't catch the response to the
last question about any clauses in the merger agreement about problems with
their pipeline, whether there's an out for Lundbeck, and also if any Danish
approvals are required.

Claus Braestrup:

We have conducted a due diligence on the pipeline and the project, which means
that we have looked into the patent estate, we have looked into all the
individual projects. We have had a number of people for a long time to go
through the various phases, which means that we know the projects very well,
and we know the intellectual property behind that very well. The only current
project -- and there is no clause in the present agreement that we can claim
refund for anything that we have overlooked, but we don't expect that we have
overlooked significant issues. Regarding the regulatory approvals, these are
presently only for the project which is in Phase I, and Synaptic has achieved
all the necessary approvals from the U.S. regulatory authorities and IND, and
they have conducted the Phase I in the U.S. and they will also be able under
that IND to conduct a Phase II clinical trial, or if we would like to conduct
studies in Europe we would of course have to address the European regulatory
authorities, but we don't consider that to be an issue.

Jung:

O.K. Are there any other regulatory approvals such as Hart- Scott-Rodino or
Danish approval?

Claus:

No, there are no other approvals that we need in that respect to go forward.

Jung:

O.K., thank you.







                                                                             9

Operator:

Thank you. Our next question is from Josh Woods, please go ahead, announcing
your company name.

Josh Woods:

Hi, guys, Josh Woods from JP Morgan. A quick few follow-up questions on the
financials of the deal, particularly the balance sheet, and how that might
impact the income statement next year. Just looking through the financial
filings of Synaptic, I see that there's also some preferred stock outstanding.
Can you give a sense as to how this will be financed in terms of timing,
either through debt and how that may impact the P & L? Thank you.

Claus Braestrup:

The preferred stock outstanding will be dealt with -- which are held by
Warburg Pincus, and they will be, as part of the AGN, where the shareholders
vote will be conducted, they will be paid out at a price of $6.50.

Josh Woods:

O.K., so the $6.50 pertains to both the preferred and the common equity?

Claus Braestrup:

That's correct.

Josh Woods:

O.K. And that will be financed through balance sheet cash at Lundbeck, or will
you be --?

Claus Braestrup:

The transaction will be paid in cash.

Josh Woods:

O.K.  That's all, thank you.

Operator:

Once again, if you'd like to ask a question, please press the number one on
your keypad. Our next question is from Annette Larsen from Carnegie, please go
ahead.







                                                                            10

Annette Larsen:

Annette Larsen from Carnegie. I have one question regarding two Synaptic
partners. Does Synaptic have any obligations to these partners, and is there
any potential conflict of interest to what you expect to get out of the
pipeline, and will there be any financial effects from any such obligations?

Claus Braestrop:

Currently, Synaptic is entertaining a collaboration project with Grunenthal on
compounds for pain, and also they have a collaboration with Kissei on G
Coupled Receptors. We of course have looked into those corporations, and first
of all they are not major, and secondly they do not restrict us in any of the
value that we would like to take out of the collaboration with Synaptic. Then
there are certain rights still to previous collaborations will not in any way
(???) our expectation of the EPR value at the company.

Annette Larsen:

O.K.  Thank you.

Operator:

Thank you, once again, if you have a question, please press the number one on
your telephone keypad, and the hash or the pound to cancel. [Pause] There
appears to be no further questions at this time. Claus, I'll hand the
conference back to you for any further remarks.

Claus:

I'd like to thank you all for attending this teleconference, and we look
forward to speaking to you again, by the latest when we come with our 2002
result in March, 2003. Thank you.

O.K.  Thank you.